Irinotecan as 3rd Line Therapy in Gastric Cancer

Inclusion Criteria: * Histologically confirmed advanced or metastatic adenocarcinoma of the stomach * Have failed for 2 lines of chemotherapy * Life expectancy of more than 3 months * ECOG performance scale ≤ 2 * At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan) * Duration from the last therapy is more than 6 weeks for nitroso or mitomycin * More than 4 weeks for operation or radiotherapy * More than 4 weeks for cytotoxic agents or growth inhibitors * Adequate hepatic, renal, heart, and hematologic functions (platelets \> 100 × 109/L, neutrophil \> 1.5× 109/L, serum creatinine ≤ 1×upper limit of normal(ULN), total bilirubin within 1× ULN, and serum transaminase≤2.5×the ULN). * Exclusion of pregnant or lactating women Exclusion Criteria: * Previously receiving irinotecan treatment * Participated other clinical trials within 4 weeks * Known Gilbert Syndrome or other biliary tract obstructive disease * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * Evidence of CNS metastasis * Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure * Receiving the therapy of thrombolysis or anticoagulation * Disability of serious uncontrolled intercurrence infection. * Uncontrolled pleural effusion and ascites